This HTML5 document contains 61 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n12http://localhost/temp/predkladatel/
n4http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n13http://linked.opendata.cz/ontology/domain/vavai/
n5http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n14http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n15http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14110%2F10%3A00067349%21RIV14-MSM-14110___/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n10http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14110%2F10%3A00067349%21RIV14-MSM-14110___
rdf:type
n13:Vysledek skos:Concept
dcterms:description
The monitoring of hOCT1 mRNA expression in patients with chronic myelogenous leukemia (CML) was used for predicting the response to imatinib treatment. However, different cell populations from patients who received various degrees of pretreatment were used for this analysis. Therefore, several biases in the results and their interpretation may arise. We investigated hOCT1 mRNA expression in different cell populations of peripheral blood (PB) from healthy volunteers and in imatinib nave de novo CML patients by analyzing changes in hOCT1 mRNA expression during the first 6 months of imatinib therapy. The hOCT1 mRNA expression was significantly higher in PB polymorphonuclears compared to mononuclears. The hOCT1 mRNA expression in total PB leukocytes is, therefore, preferentially determined by the percentage of polymorphonuclears. Expression in each analyzed group of cells was always significantly lower in imatinib nave de novo CML patients compared to healthy volunteers. The monitoring of hOCT1 mRNA expression in patients with chronic myelogenous leukemia (CML) was used for predicting the response to imatinib treatment. However, different cell populations from patients who received various degrees of pretreatment were used for this analysis. Therefore, several biases in the results and their interpretation may arise. We investigated hOCT1 mRNA expression in different cell populations of peripheral blood (PB) from healthy volunteers and in imatinib nave de novo CML patients by analyzing changes in hOCT1 mRNA expression during the first 6 months of imatinib therapy. The hOCT1 mRNA expression was significantly higher in PB polymorphonuclears compared to mononuclears. The hOCT1 mRNA expression in total PB leukocytes is, therefore, preferentially determined by the percentage of polymorphonuclears. Expression in each analyzed group of cells was always significantly lower in imatinib nave de novo CML patients compared to healthy volunteers.
dcterms:title
The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population
skos:prefLabel
The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population
skos:notation
RIV/00216224:14110/10:00067349!RIV14-MSM-14110___
n3:aktivita
n17:V n17:Z
n3:aktivity
V, Z(MSM0021622430)
n3:cisloPeriodika
7
n3:dodaniDat
n10:2014
n3:domaciTvurceVysledku
n4:4585623 n4:5755476 n4:8940762 n4:3004880 n4:5378605 n4:1344153 n4:3715434 n4:4376285
n3:druhVysledku
n19:J
n3:duvernostUdaju
n16:S
n3:entitaPredkladatele
n15:predkladatel
n3:idSjednocenehoVysledku
247906
n3:idVysledku
RIV/00216224:14110/10:00067349
n3:jazykVysledku
n6:eng
n3:klicovaSlova
RESIDUAL DISEASE DETECTION; POLYMERASE-CHAIN-REACTION; CHRONIC MYELOID-LEUKEMIA; CANCER PROGRAM; OCT-1 ACTIVITY; IMATINIB; RESISTANCE; DETERMINANT; EUROPE
n3:klicoveSlovo
n8:RESIDUAL%20DISEASE%20DETECTION n8:RESISTANCE n8:POLYMERASE-CHAIN-REACTION n8:IMATINIB n8:DETERMINANT n8:EUROPE n8:CANCER%20PROGRAM n8:OCT-1%20ACTIVITY n8:CHRONIC%20MYELOID-LEUKEMIA
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[CDA4FCBC4A42]
n3:nazevZdroje
American Journal of Hematology
n3:obor
n18:FD
n3:pocetDomacichTvurcuVysledku
8
n3:pocetTvurcuVysledku
9
n3:rokUplatneniVysledku
n10:2010
n3:svazekPeriodika
85
n3:tvurceVysledku
Rázga, Filip Jurček, Tomáš Dvořáková, Dana Cetkovský, Petr Mayer, Jiří Timilsina, Shira Ráčil, Zdeněk Žáčková, Daniela Burešová, Lucie
n3:wos
000279506200018
n3:zamer
n5:MSM0021622430
s:issn
0361-8609
s:numberOfPages
4
n14:doi
10.1002/ajh.21722
n12:organizacniJednotka
14110